Covariate | Patients receiving BI (N=113) n (%)/mean±SD | Patients receiving OAD (N=408) n (%)/mean±SD | p Value |
---|---|---|---|
Number of patients on ≥1 OAD | 51 (45.1) | 408 (100) | |
Number of patients on ≥2 OADs | 9 (8.0) | 46 (11.3) | 0.39 |
Type of OAD/other non-insulin therapy | |||
β-blockers (C07A) | 12 (10.6) | 49 (12.0) | 0.74 |
Biguanides (A10BA, ie, metformin) | 33 (29.2) | 335 (82.1) | <0.001 |
Sulfonylureas (A10BB/A10BC) | 8 (7.1) | 28 (6.9) | 1 |
α-glucosidase Inhibitors (A10BF) | 0 (0) | 2 (0.5) | 1 |
Thiazolidinediones (A10BG) | 0 (0) | 0 (0) | – |
DPP-4 inhibitors (A10BH) | 5 (4.4) | 39 (9.6) | 0.09 |
Other blood glucose-lowering drugs (A10BX) | 8 (7.1) | 18 (4.4) | 0.32 |
Combinations (A10BD) | 6 (5.3) | 32 (7.8) | 0.42 |
Type of BI | |||
IGlarg | 32 (28.3) | NA | NA |
Mean dose (units/kg/day)* | 0.18±0.07 | ||
IDet | 30 (26.5) | NA | NA |
Mean dose (units/kg/day)* | 0.19±0.19 | ||
NPH | 51 (45.2) | NA | NA |
Mean dose (units/kg/day)* | 0.17±0.10 |
Bold indicates significance. p Values for continuous data were provided by pooled univariate linear regression models. p Values for dichotomous variables correspond to Fisher's exact tests.
*Based on non-missing values.
BI, basal insulin; DPP-4, dipeptidyl peptidase-4; IDet, insulin detemir; IGlarg, insulin glargine; NA, not applicable; NPH, neutral protamine Hagedorn; OAD, oral antidiabetic drug.